Yohannes Ghebre (Baylor College of Medicine, Houston, TX, US) discusses the rationale and clinical evidence to date for using proton pump inhibitors (PPIs) to treat idiopathic pulmonary fibrosis (IPF).
Questions1. What are the limitations of the currently approved drugs, pirfenidone and nintedanib, in idiopathic pulmonary fibrosis (IPF)? (0:11)
2. What is the rationale for using proton pump inhibitors (PPIs) to treat IPF? (1:08)
3. What clinical evidence exists for the use of PPIs in IPF? (2:06)
4. What (if any) are the potential safety issues in using PPIs to treat patients with IPF? (2:55)
5. What further studies are needed? (3:26)
Speaker disclosure: Yohannes Ghebre is an inventor on a patent, owned by Stanford University, that protects the use of proton pump inhibitors (PPIs) for the treatment of idiopathic pulmonary fibrosis (IPF).
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.